Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adverse outcomes and maternal complications in pregnant women with severe-critical COVID-19: a tertiary center experience.
Sinaci S, Tanacan A, Besimoglu B, Menekse Beser D, Uyan Hendem D, Tugrul Ersak D, Atalay A, Kaya E, Ozden Tokalioglu E, Cankar Dal H, Ocal DF, Erdem D, Izdes S, Moraloglu Tekin O, Ates İ, Turan S, Sahin D. Sinaci S, et al. Among authors: ates i. J Perinat Med. 2023 May 3;51(7):874-885. doi: 10.1515/jpm-2022-0564. Print 2023 Sep 26. J Perinat Med. 2023. PMID: 37134274
Impact of Inflammation-Related Genes on COVID-19: Prospective Study at Turkish Cohort.
Ceylan AC, Çavdarlı B, Ceylan GG, Topçu V, Satılmış SBA, Bektaş ŞG, Kalem AK, Kayaaslan B, Eser F, Kalkan EA, İnan O, Hasanoğlu İ, Yüksel S, Ateş İ, İzdeş S, Güner R, Gündüz CNS. Ceylan AC, et al. Among authors: ates i. Tohoku J Exp Med. 2023 Nov 11;261(3):179-185. doi: 10.1620/tjem.2023.J071. Epub 2023 Aug 25. Tohoku J Exp Med. 2023. PMID: 37635061 Free article.
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study.
Ates I, Batirel A, Aydin M, Karadag FY, Erden A, Kucuksahin O, Armagan B, Guven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Omma A, Kara A. Ates I, et al. Vaccines (Basel). 2023 Jul 12;11(7):1234. doi: 10.3390/vaccines11071234. Vaccines (Basel). 2023. PMID: 37515050 Free PMC article.
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.
Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Aslan AF, Bayram A, Mazicioglu M, Kalin Unuvar G, Yuce ZT, Aydin G, Kaya RK, Ates I, Kara A, Ozdarendeli A. Sezer Z, et al. Among authors: ates i. Vaccines (Basel). 2024 Jan 29;12(2):140. doi: 10.3390/vaccines12020140. Vaccines (Basel). 2024. PMID: 38400124 Free PMC article.
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
Ates I, Stuart C, Rathbone T, Barzi M, He G, Major AM, Shankar V, Lyman RA, Angner SS, Mackay TFC, Srinivasan S, Farris AB, Bissig KD, Cottle RN. Ates I, et al. Hepatol Commun. 2024 Apr 26;8(5):e0424. doi: 10.1097/HC9.0000000000000424. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38668730 Free article.
224 results